Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer

Journal of Cancer Research and Clinical Oncology

Volumn 140, Issue 11, 2014, Pages 1849-1861

  Litovkin, Kirill ^a,h   Joniau, Steven ^b,c   Lerut, Evelyne ^b,d   Laenen, Annouschka ^c   Gevaert, Olivier ^e   Spahn, Martin ^f,g   Kneitz, Burkhard ^g   Isebaert, Sofie ^b,c   Haustermans, Karin ^b,c   Beullens, Monique ^a   Van Eynde, Aleyde ^a   Bollen, Mathieu ^a  

^a LABORATORY OF MOLECULAR AND CELLULAR SIGNALING   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d DEPARTMENT OF IMAGING AND PATHOLOGY   (Belgium)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF BERN   (Switzerland)

^g UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^h ODESSA NATIONAL MEDICAL UNIVERSITY   (Ukraine)

Author keywords

Biochemical recurrence; DNA methylation; Prognosis; Prostate cancer

Indexed keywords

HOMEOBOX D3 PROTEIN; PEPTIDES AND PROTEINS; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TRANSCRIPTION FACTOR PITX2; TUDOR DOMAIN CONTAINING 1 PROTEIN; UNCLASSIFIED DRUG; CARRIER PROTEIN; HOMEODOMAIN PROTEIN; HOXA4 PROTEIN, HUMAN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; PROSTATE SPECIFIC ANTIGEN; RASSF1 PROTEIN, HUMAN; TDRD1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; BIOCHEMICAL RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; POLYMERASE CHAIN REACTION; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROSTATE HYPERTROPHY; RECURRENT DISEASE; RISK FACTOR; VERY ELDERLY; BLOOD; GENETICS; MIDDLE AGED; PATHOLOGY; PROMOTER REGION; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; TUMOR CELL LINE; TUMOR RECURRENCE;

AGED; AGED, 80 AND OVER; CARRIER PROTEINS; CELL LINE, TUMOR; DNA METHYLATION; HOMEODOMAIN PROTEINS; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84919484848     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-014-1738-8     Document Type: Article

References (37)

1. Ahmed H, Cappello F, Rodolico V, Vasta GR (2009) Evidence of heavy methylation in the galectin 3 promoter in early stages of prostate adenocarcinoma: development and validation of a methylated marker for early diagnosis of prostate cancer. Transl Oncol 2:146–156
2. Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid HP, van Poppel H, Wolff J, Zattoni F (2005) EAU guidelines on prostate cancer. Eur Urol 48:546–551
3. Bañez LL, Sun L, van Leenders GJ, Wheeler TM, Bangma CH, Freedland SJ, Ittmann MM, Lark AL, Madden JF, Hartman A et al (2010) Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. J Urol 184:149–156
4. Chao C, Chi M, Preciado M, Black MH (2013) Methylation markers for prostate cancer prognosis: a systematic review. Cancer Causes Control 24:1615–1641
5. Chung W, Kwabi-Addo B, Ittmann M, Jelinek J, Shen L, Yu Y, Issa JP (2008) Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling. PLoS ONE 3:e2079
6. Cooperberg MR, Cowan J, Broering JM, Carroll PR (2008) High-risk prostate cancer in the United States, 1990–2007. World J Urol 26:211–218
7. De Smet C, Loriot A (2013) DNA hypomethylation and activation of germline-specific genes in cancer. Adv Exp Med Biol 754:149–166
8. Donninger H, Vos MD, Clark GJ (2007) The RASSF1A tumor suppressor. J Cell Sci 120:3163–3172
9. Freedland SJ (2011) Screening, risk assessment, and the approach to therapy in patients with prostate cancer. Cancer 117:1123–1135
10. Friedman J, Hastie T, Tibshirani К (2010) Regularization paths for generalized linear models via coordinate descent. J Stat Softw 33:1–22
11. Harbeck N, Nimmrich I, Hartmann A, Ross JS, Cufer T, Grützmann R, Kristiansen G, Paradiso A, Hartmann O, Margossian A et al (2008) Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients. J Clin Oncol 26:5036–5042
12. Harrell FE (2002) Regression modeling strategies. With applications to linear models logistic regression and survival analysis. Springer, New-York
13. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F et al (2014) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65:124–137
14. Jhavar S, Reid A, Clark J, Kote-Jarai Z, Christmas T, Thompson A, Woodhouse C, Ogden C, Fisher C, Corbishley C et al (2008) Detection of TMPRSS2-ERG translocations in human prostate cancer by expression profiling using Gene Chip Human Exon 1.0 ST arrays. J Mol Diagn 10:50–57
15. Kacprzyk LA, Laible M, Andrasiuk T, Brase JC, Börno ST, Fälth M, Kuner R, Lehrach H, Schweiger MR, Sültmann H (2013) ERG induces epigenetic activation of Tudor domain-containing protein 1 (TDRD1) in ERG rearrangement-positive prostate cancer. PLoS ONE 8:e59976
16. Kron KJ, Liu L, Pethe VV, Demetrashvili N, Nesbitt ME, Trachtenberg J, Ozcelik H, Fleshner NE, Briollais L, van der Kwast TH et al (2010) DNA methylation of HOXD3 as a marker of prostate cancer progression. Lab Invest 90:1060–1067
17. Liu L, Kron KJ, Pethe VV, Demetrashvili N, Nesbitt ME, Trachtenberg J, Ozcelik H, Fleshner NE, Briollais L, van der Kwast TH et al (2011) Association of tissue promoter methylation levels of APC, TGFβ2, HOXD3, and RASSF1A with prostate cancer progression. Int J Cancer 129:2454–2462
18. Loriot A, Boon T, De Smet C (2003) Five new human cancer-germline genes identified among 12 genes expressed in spermatogonia. Int J Cancer 105:371–376
19. Mahapatra S, Klee EW, Young CY, Sun Z, Jimenez RE, Klee GG, Tindall DJ, Donkena KV (2012) Global methylation profiling for risk prediction of prostate cancer. Clin Cancer Res 18:2882–2895
20. Maier S, Nimmrich I, Koenig T, Eppenberger-Castori S, Bohlmann I, Paradiso A, Spyratos F, Thomssen C, Mueller V, Nährig J et al (2007) DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients–technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) Patho biology group. Eur J Cancer 43:1679–1686
21. Naggara O, Raymond J, Guilbert F, Roy D, Weill A, Altman DG (2011) Analysis by categorizing or dichotomizing continuous variables is inadvisable: an example from the natural history of unruptured aneurysms. AJNR Am J Neuroradiol 32:437–440
22. Nelson WG, De Marzo AM, Yegnasubramanian S (2009) Minireview: epigenetic alterations in human prostate cancers. Endocrinology 150:3991–4002
23. Pan J, Chen J, Zhang B, Chen X, Huang B, Zhuang J, Mo C, Qiu S (2013) Association between RASSF1A promoter methylation and prostate cancer: a systematic review and meta-analysis. PLoS ONE 8:e75283
24. Park JY (2010) Promoter hypermethylation in prostate cancer. Cancer Control 17:245–255
25. Paulo P, Ribeiro FR, Santos J, Mesquita D, Almeida M, Barros-Silva JD, Itkonen H, Henrique R, Jerónimo C, Sveen A et al (2012) Molecular sub typing of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements. Neoplasia 14:600–611
26. Pellacani D, Kestoras D, Droop AP, Frame FM, Berry PA, Lawrence MG, Stower MJ, Simms MS, Mann VM, Collins AT et al (2014) DNA hypermethylation in prostate cancer is a consequence of aberrant epithelial differentiation and hyperproliferation. Cell Death Differ 21:761–773
27. Phé V, Cussenot O, Rouprêt M (2010) Methylated genes as potential biomarkers in prostate cancer. BJU Int 105:1364–1370
28. Ploussard G, Epstein JI, Montironi R, Carroll PR, Wirth M, Grimm MO, Bjartell AS, Montorsi F, Freedland SJ, Erbersdobler A et al (2011) The contemporary concept of significant versus insignificant prostate cancer. Int Braz J Urol 37:405–406
29. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ (2004) Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: longterm results. J Urol 172:910–914
30. Schulz W (2005) Qualified promise: DNA methylation assays for the detection and classification of human cancers. J Biomed Biotechnol 2005:227–229
31. Spahn M, Joniau S, Gontero P, Fieuws S, Marchioro G, Tombal B, Kneitz B, Hsu CY, Van Der Eeckt K, Bader P et al (2010a) Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. Eur Urol 58:1–7
32. Spahn M, Kneitz S, Scholz CJ, Stenger N, Rüdiger T, Ströbel P et al (2010b) Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer 127:394–403
33. Swanson GP, Hussey MA, Tangen CM, Chin J, Messing E, Canby-Hagino E, Forman JD, Thompson IM, Crawford ED, SWOG 8794 (2007) Predominant treatment failure in post prostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol 25:2225–2229
34. Swanson GP, Yu C, Kattan MW, Hermans MR (2011) Validation of postoperative nomograms in prostate cancer patients with long-term follow-up. Urology 78:105–109
35. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G et al (2009) Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 181:956–962
36. Weiss G, Cottrell S, Distler J, Schatz P, Kristiansen G, Ittmann M, Haefliger C, Lesche R, Hartmann A, Corman J et al (2009) DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy. J Urol 181:1678–1685
37. Xu B, Chevarie-Davis M, Chevalier S, Scarlata E, Zeizafoun N, Dragomir A, Tanguay S, Kassouf W, Aprikian A, Brimo F (2014) The prognostic role of ERG immunopositivity in prostatic acinar adenocarcinoma: a study including 454 cases and review of the literature. Hum Pathol 45:488–497